Company Filing History:
Years Active: 2008-2010
Title: **Charlotta Enerbäck: Innovator in Breast Cancer Research**
Introduction
Charlotta Enerbäck is a notable inventor based in Gothenburg, Sweden. She has made significant contributions to the field of cancer research, particularly in diagnosing high-grade ductal carcinoma in situ (DCIS). Her work is characterized by the innovative methods she has developed for detecting this type of cancer.
Latest Patents
Charlotta holds one patent titled **"Psoriasin expression by breast epithelial cells."** This invention outlines methods for diagnosing high-grade DCIS by measuring the level of HID-5 in body fluids such as blood or urine from subjects suspected of having, or at risk of developing, this condition. Additionally, her patent includes methods of measuring HID-5 gene expression in breast tissue. The invention also provides a groundbreaking approach to inhibiting the expression of HID-5 protein in DCIS cells and offers therapeutic methods for subjects at risk of high-grade DCIS.
Career Highlights
Charlotta Enerbäck is affiliated with the Dana-Farber Cancer Institute, a prestigious institution renowned for its cancer research and treatment. Her work at this institute underscores her dedication to advancing the understanding and treatment of breast cancer. Through her innovative approaches, she contributes vital knowledge that may help improve diagnostic and therapeutic options for patients.
Collaborations
In her professional journey, Charlotta has collaborated with Kornelia Polyak, a respected figure in the field of cancer research. Their combined efforts amplify the impact of their research and reflect a commitment to scientific excellence. This collaboration has the potential to pave the way for further breakthroughs in the understanding of breast cancer.
Conclusion
Charlotta Enerbäck's contributions to breast cancer research through her innovative patent demonstrate her passion for improving diagnostics and treatment approaches. Her work not only reflects her individual talent as an inventor but also highlights the importance of collaboration in advancing medical research. As she continues her efforts at the Dana-Farber Cancer Institute, her work is poised to significantly influence the field of oncology.